Osteoporosis
Mostrando 1-12 de 656 artigos, teses e dissertações.
-
1. Em qual idade devemos solicitar Densitometria óssea para homem e mulher?
A prevalência de osteoporose e a incidência de fraturas variam de acordo com o sexo e a raça. Devido ao aumento na expectativa de vida das populações, a osteoporose é atualmente reconhecida como importante questão em termos de saúde pública. Afeta indivíduos de maior idade, sobretudo mulheres na pós-menopausa. Uma mulher de 50 anos apresenta um
Núcleo de Telessaúde Rio Grande do Sul. Publicado em: 12/06/2023
-
2. An inconvenient status in anti-osteoporotic treatment process: corticosteroid use
SUMMARY OBJECTIVE: There are limited studies investigating the comparison of the efficacy of anti-osteoporotic drugs in different conditions resulting in osteoporosis in older adults. This study aimed to compare the effectiveness of anti-osteoporotic agents in older adults with or without glucocorticoid-induced osteoporosis. METHODS: This retrospective stu
Revista da Associação Médica Brasileira. Publicado em: 2022
-
3. Male osteoporosis
ABSTRACT Osteoporosis, a disease classically attributed to postmenopausal women, is underappreciated, underdiagnosed, and undertreated in men. However, it is not uncommon for osteoporotic fractures to occur in men. About 40% of fractures occur in men with an incidence that has increased over the years. After a first fracture, the risk of a subsequent episode
Archives of Endocrinology and Metabolism. Publicado em: 2022
-
4. The why and how of sequential and combination therapy in osteoporosis. A review of the current evidence
ABSTRACT It is now well recognized that over the lifetime of a patient with osteoporosis, more than one medication will be needed to treat the disease and to decrease fracture risk. Though current gaps in osteoporosis therapy can be potentially mitigated with sequential and combination regimens, how to move seamlessly amongst the multiple treatments currentl
Archives of Endocrinology and Metabolism. Publicado em: 2022
-
5. Definition and management of very high fracture risk in women with postmenopausal osteoporosis: a position statement from the Brazilian Society of Endocrinology and Metabolism (SBEM) and the Brazilian Association of Bone Assessment and Metabolism (ABRASSO)
ABSTRACT Several drugs are available for the treatment of osteoporosis in postmenopausal women. Over the last decades, most patients requiring pharmacological intervention were offered antiresorptive drugs as first-line therapy, while anabolic agents were considered a last resource for those with therapeutic failure. However, recent randomized trials in pati
Archives of Endocrinology and Metabolism. Publicado em: 2022
-
6. Diabetes and bone
Abstract Globally, one in 11 adults has diabetes mellitus of which 90% have type 2 diabetes. The numbers for osteoporosis are no less staggering: 1 in 3 women has a fracture after menopause, and the same is true for 1 in 5 men after the age of 50 years. Aging is associated with several physiological changes that cause insulin resistance and impaired insulin
Archives of Endocrinology and Metabolism. Publicado em: 2022
-
7. Facing Osteoporosis: Is Hormonal Therapy Losing an Opportunity to be Used? The Role of Gynecologists
Revista Brasileira de Ginecologia e Obstetrícia. Publicado em: 2022
-
8. 3.0-tesla magnetic resonance imaging in the assessment of postmenopausal osteoporosis: are technological advances capable of replacing bone densitometry?
Radiologia Brasileira. Publicado em: 2022
-
9. Celiac disease and bone
Abstract Celiac disease (CD) is an autoimmune disorder characterized by small intestinal inflammation triggered by gluten ingestion in genetically-predisposed individuals. A frequent extra-intestinal manifestation of CD is metabolic bone disease which contributes to an increased risk of fracture. The mechanisms underlying bone disease in CD remain incomplete
Archives of Endocrinology and Metabolism. Publicado em: 2022
-
10. Anabolic therapy for osteoporosis: update on efficacy and safety
ABSTRACT Anabolic agents for the treatment of osteoporosis increase bone density, improve bone strength, and reduce fracture risk. They are distinguished from antiresorptive drugs by their property of increasing osteoblastic bone formation. Teriparatide and abaloparatide are parathyroid hormone receptor agonists that increase bone remodeling with bone format
Archives of Endocrinology and Metabolism. Publicado em: 2022
-
11. Long-term consequences of osteoporosis therapy with denosumab
ABSTRACT Denosumab (DMAb) is a human monoclonal antibody used as an antiresorptive drug in the treatment of osteoporosis. Approval at a dosage of 60 mg every 6 months was based on the results of the randomized, placebo-controlled trial (FREEDOM). The design of this 3-year study included an extension for up to 10 years. Those who were randomized to DMAb conti
Archives of Endocrinology and Metabolism. Publicado em: 2022
-
12. Performance of the Fracture Risk Assessment Tool Associated with Muscle Mass Measurements and Handgrip to Screen for the Risk of Osteoporosis in Young Postmenopausal Women
Resumo Objetivo Avaliar a melhora da precisão da Fracture Risk Assessment Tool (Ferramenta de Avaliação do Risco de Fraturas, FRAX, em inglês) no rastreio do risco de desenvolver osteoporose em mulheres jovens pós-menopáusicas com a associação de medidas clínicas de massa muscular e preensão manual. Métodos Uma amostra de mulheres pós-menopá
Revista Brasileira de Ginecologia e Obstetrícia. Publicado em: 2022